Moderna: cross-border access for the specialty portfolio

Quick orientation

Moderna, Inc. is a US biotechnology company headquartered in Cambridge, Massachusetts, focused on mRNA therapeutics and vaccines. Moderna emerged as a global leader during the COVID-19 pandemic with its Spikevax mRNA vaccine and has expanded its commercial portfolio to include the respiratory syncytial virus (RSV) vaccine mRESVIA. The company trades on NASDAQ as MRNA. FDA approval scale spans two marketed mRNA vaccines as of mid-2026, with an active pipeline across additional respiratory vaccines (combination influenza-COVID, flu standalone, CMV), cancer vaccines (personalised cancer vaccine in melanoma in partnership with Merck), and rare-disease mRNA therapeutics. Moderna also operates substantial development programs in autoimmune disease and additional infectious disease indications.

Moderna portfolio in cross-border NPP scope

Spikevax (mRNA-1273; elasomeran for original strain and variant-updated formulations) is an FDA-approved mRNA vaccine for the prevention of COVID-19. Spikevax received initial FDA Emergency Use Authorisation in December 2020 and full FDA approval in January 2022, with subsequent variant-updated formulations approved each season. Intramuscular injection. The product requires frozen storage at -25 to -15 degrees C (long term) or refrigerated handling for shorter periods.

mRESVIA (mresvia; mRNA-1345) is an FDA-approved mRNA vaccine for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older (FDA approval May 2024) and 18-59 with increased risk (April 2025 expansion). Intramuscular injection.

Moderna's pipeline includes mRNA-1083 (combination influenza-COVID-19 vaccine), mRNA-1010 (seasonal influenza), mRNA-1647 (cytomegalovirus), mRNA-1273.045 (personalised cancer vaccine in combination with Keytruda, partnered with Merck), and several rare-disease mRNA therapeutics including mRNA-3927 (propionic acidemia) and mRNA-3705 (methylmalonic acidemia). These are investigational and not in NPP scope.

Vaccine cross-border distribution is highly regulated and operationally distinct from specialty pharmaceutical NPP. Vaccines for routine immunisation programs are typically procured through national immunisation programs, GAVI, or country-level public health agencies rather than through patient-level cross-border NPP. Reserve Meds does not coordinate routine seasonal COVID-19 or RSV vaccines through patient-level cross-border channels because the operational and regulatory frameworks for vaccines differ substantially from specialty pharmaceutical NPP, and country-of-residence public health systems are typically the appropriate access pathway.

Why patients route through cross-border NPP

Patient-level cross-border NPP demand for Moderna products is limited. The Moderna commercial portfolio in mid-2026 consists primarily of vaccines, and vaccine access for international patients is generally handled through country-level public health programs, private clinic immunisation services, or vaccine tourism rather than through patient-level wholesale-sourced cross-border channels. We list Moderna on the manufacturer index for completeness and to receive any clinical-stage rare-disease mRNA therapy inquiry that may emerge as the rare-disease pipeline progresses, but we do not currently coordinate seasonal vaccine shipments.

If Moderna's pipeline mRNA therapeutics for rare metabolic diseases (propionic acidemia, methylmalonic acidemia, and others) receive FDA approval, those products would fall within standard Reserve Meds cross-border NPP scope as ultra-rare-disease specialty products. Reserve Meds will activate full coordination at that time.

Common cross-border destinations

If and when Moderna's pipeline rare-disease mRNA therapeutics receive FDA approval, expected high-frequency NPP destinations will mirror the broader rare-metabolic-disease cross-border pattern: the United Arab Emirates, Saudi Arabia, India, Qatar, and Turkey, with referral concentrations at pediatric metabolic centers in major academic medical centers across these jurisdictions.

Manufacturer engagement posture

Reserve Meds does not currently coordinate Moderna vaccine products through patient-level cross-border NPP channels because vaccine access is appropriately handled through country-level public health and immunisation programs. We are not affiliated with Moderna. For Moderna medical affairs or future commercial teams interested in cross-border patient pathways for rare-disease mRNA therapeutics once those receive FDA approval, our BD contact is [email protected].

What Reserve Meds provides

For any future Moderna rare-disease mRNA therapeutic that receives FDA approval, Reserve Meds will coordinate: prescription verification with the treating physician (typically a metabolic geneticist or specialist); genetic confirmation documentation review; DSCSA serialized chain-of-custody from Moderna through licensed US wholesalers to the named patient; cold-chain or frozen-chain shipping per product specification with temperature data-loggers; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator from prescription to delivery.

Clinical governance and prescription review

Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.

Supply chain integrity

Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.

Destination-country regulatory pathways

Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.

What to expect through the coordination process

Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.

Not affiliated with the manufacturer

Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.

Privacy and data handling

Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.

Next step for patients

Patients seeking routine COVID-19 or RSV vaccination should consult their local public health authority or a clinician in their country of residence. Start a request › (for non-vaccine specialty product inquiries)

Next step for Moderna teams

Moderna medical affairs or future commercial teams interested in cross-border patient pathways for rare-disease mRNA therapeutics can reach our BD team at [email protected].

Reserved for you.